title: Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population.
abstract: BACKGROUND
  Genome-wide association studies have recently shown that the rs12979860 polymorphism in IL28B is associated with the response to chronic hepatitis C treatment. The aim of this study was to investigate whether rs12979860 could be used as a predictive marker for end-of-treatment response (ETR) or sustained virological response (SVR) in the Chinese Han population.
  
  
  METHODS
  The rs12979860 genotype was detected in 259 individuals infected with HCV by DNA sequencing. Among them, 120 patients were administered complete pegylated interferon-α and ribavirin combination therapy and 92 patients were followed for 24 weeks after the cessation of treatment and were divided into different groups according to outcomes of treatment.
  
  
  RESULTS
  The rs12979860 genotype CC was the primary genotype (87.64%, 227/259) and genotype TT was found in only one individual within this cohort. The patients with the rs12979860 genotype CC had higher rates of ETR (P=0.0044) and SVR (P=0.0046) than the patients with N-CC (CT or TT). In multivariate analyses, the rs12979860 genotype CC was associated with a substantial difference in rates of achieving ETR (odds ratio [OR] 8.983, 95% confidence interval [CI] 2.173-37.145; P=0.0024) and SVR (OR 24.298, 95% CI 2.27-259.90; P=0.0083).
  
  
  CONCLUSIONS
  This study demonstrated for the first time that the rs12979860 variation in IL28B could be a predictor of ETR and SVR in Chinese Han patients infected with HCV. The high frequency of the rs12979860 genotype CC might explain why the SVR rate is higher than that of the average global population.
authors: Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiaotong University, School of Medicine, China.
authors: Xiang-Wei
authors: XW
authors: Liao
authors: Yun
authors: Y
authors: Ling
authors: Xin-Hua
authors: XH
authors: Li
authors: Yue
authors: Y
authors: Han
authors: Shen-Ying
authors: SY
authors: Zhang
authors: Lei-Lei
authors: LL
authors: Gu
authors: De-Ming
authors: DM
authors: Yu
authors: Bi-Lian
authors: BL
authors: Yao
authors: Dong-Hua
authors: DH
authors: Zhang
authors: Gen-Di
authors: GD
authors: Jin
authors: Zhi-Meng
authors: ZM
authors: Lu
authors: Qi-Ming
authors: QM
authors: Gong
authors: Xin-Xin
authors: XX
authors: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D044466:Asian People / Q000235:genetics*; D002681:China / Q000208:ethnology; D004359:Drug Therapy, Combination; D005260:Female; D014644:Genetic Variation; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects*; D006526:Hepatitis C / Q000188:drug therapy / Q000235:genetics* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D007372:Interferons; D007378:Interleukins / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use; D011110:Polymorphism, Genetic; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome; D055815:Young Adult; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D007372:Interferons; D007378:Interleukins; D011092:Polyethylene Glycols; D012254:Ribavirin; C000624353:interferon-lambda, human; D000095022:Interferon Lambda